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Capecitabine is an oral prodrug of 5-fluorouracil (FU). Since FU concentrations achieved in malignant lesions are an important
determinant of efficacy, we investigated the intratumoral transcapillary transfer of capecitabine and its metabolites in vivo. A total of 10
patients with skin metastases from breast cancer received a daily dose of 2500mgm
 2 capecitabine administered orally in two
divided doses for 2 weeks. Microdialysis probes were inserted into a cutaneous metastasis and subcutaneous connective tissue to
evaluate the interstitial tissue pharmacokinetics of capecitabine and its metabolites 50-deoxy-5-fluorocytidine (DFCR), 50-deoxy-5-
fluorouridine (DFUR), and FU by capillary electrophoresis. As intended with the prodrug design of capecitabine, FU was present in
low concentrations in tumour interstitium (median cmax: 0.26mgml
 1) when compared with capecitabine, DFCR, and DFUR (median
cmax: 2.66, 4.22, and 2.13mgml
 1, respectively). Capecitabine and its metabolites easily penetrated malignant and healthy tissue and
equilibrated within 45min between plasma and tissue interstitium. Considering tissue exposure at the extracellular level, no significant
differences between healthy and malignant tissues were observed. Our data show that absorption and metabolism determined the
tissue pharmacokinetics of capecitabine. There was no evidence of drug tolerance, which may be attributed to impaired transcapillary
transfer into tissue, even after repeated administration as shown for three patients.
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Capecitabine is an oral prodrug of 5-fluorouracil (FU), which is
activated mainly in liver and tumour via a cascade of three
enzymes (Miwa et al, 1998). Exploiting this enzymatic cascade,
capecitabine has been rationally designed to achieve a tumour
selective accumulation of FU. This is finally carried out by the
enzyme thymidine phosphorylase, which is often highly expressed
in malignant tissue. Once built up, FU is then anabolysed
intracellularly to its cytotoxic species. In contrast, the catabolic
sequence of FU is initiated by the enzyme dihydropyrimidine
dehydrogenase and degrades FU to compounds lacking antipro-
liferative activity. The pharmacokinetics of capecitabine and its
metabolites have been described in detail when given either as
monotherapy (Budman et al, 1998; Mackean et al, 1998; Judson
et al, 1999) or after biochemical modulation with folinic acid
(Cassidy et al, 1998). In early clinical trials, capecitabine has been
used in combination with paclitaxel (Villalona-Calero et al, 1999)
or with docetaxel (Pronk et al, 2000). Both taxanes did not affect
the pharmacokinetics of capecitabine, although upregulation of
thymidine phosphorylase has been reported in tumour xenografts
(Ishitsuka, 2000) after exposure to paclitaxel or docetaxel. Mild to
moderate hepatic dysfunction had no significant influence on the
pharmacokinetics of capecitabine and its metabolites (Twelves
et al, 1999), whereas food had a profound effect on the area under
the concentration – time curve (AUC) of capecitabine (Reigner
et al, 1998).
In contrast to the well-described pharmacokinetics in blood,
data about intratumoral pharmacokinetics are scarce. In nude
mice, the enrichment of FU in tumour xenografts was remarkably
high (Ishikawa et al, 1998). In biopsies of human colon tumours,
the accumulation of FU was less favourable when compared with
the mouse model. Using tissue biopsies obtained sporadically
during routine surgery, this investigation has shown the selective
activation of capecitabine to FU in primary colorectal tumours, but
not in liver metastases when compared with surrounding healthy
liver tissue (Schu ¨ller et al, 2000).
To gain insight into tissue pharmacokinetics, we chose the
microdialysis technique as an approach for the continuous
monitoring of capecitabine and its metabolites in the extracellular
extravascular space. In the present investigation, we compare the
pharmacokinetics of capecitabine and its metabolites in blood,
malignant and healthy tissue interstitium in the form of the free,
nonprotein-bound drug. The aim of this study was to assess the
extravascular transfer of capecitabine and its metabolites into
healthy and malignant tissues and to characterise putative
differential tissues distribution as a starting point to unravel the
mechanism of unwanted side effects of this drug.
MATERIALS AND METHODS
The clinical study protocol was approved by the local ethics
committee. All patients were given a detailed description of the
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sstudy and their written informed consent was obtained. The study
was performed in accordance with the declaration of Helsinki and
the Good Clinical Practice Guideline of the European Commission.
Patient selection
Patients with a histologically confirmed diagnosis of breast cancer
with skin metastases to the chest wall suitable for the insertion of
microdialysis probes were admitted to the study. These patients
were resistant to both paclitaxel and anthracycline containing
chemotherapy regimens or had previously received cumulative
doses of 400mgm
 2 of doxorubicin or doxorubicin equivalents.
Women of childbearing potential were advised to avoid becoming
pregnant while receiving capecitabine treatment. A pregnancy test
was performed prior to the study day to exclude a present
pregnancy. Patients older than 19 years with a WHO performance
status (ECOG scale) 0, 1, or 2 were eligible. Criteria for inclusion
were as follows: histologic proof of breast cancer, age 19–80 years,
Karnofsky performance status 480%, absence of distant disease,
adequate haematologic parameters (white blood count
X3.500ml
 1, haemoglobin level 49gdl
 1, and platelet count
X100.000ml
 1), adequate hepatic (serum bilirubin o1.5mgdl
 1,
transaminases o twice the upper limit of normal) and renal
functions (serum creatinine o1.5mgdl
 1).
Patients with a pathologic coagulation time presenting a risk for
probe insertion, that is, a PTT 441.0s or PTT o75%, and a
known hypersensitivity to FU were excluded from the study.
Treatment plan
The daily dose of capecitabine was 2500mgm
 2 administered
orally with food according to the manufacturer’s instructions for 2
consecutive weeks followed by a 1-week rest period (¼1 cycle).
The daily dose was given orally in two divided doses (approxi-
mately 12h apart) within 30min after a meal. Tablets (Xeloda
s,
Roche, Basel, Switzerland) were swallowed with tap water.
Microdialysis
Patients were in a supine position throughout the study period.
Commercially available microdialysis probes (CMA 10
s, CMA,
Stockholm, Sweden) were inserted into a suitable cutaneous
metastasis. A second microdialysis probe was inserted horizontally
into the subcutaneous connective tissue of one thigh. The surface
of the disinfected skin was punctured according to a previously
described procedure (Mu ¨ller et al, 1995). The position of the
probes in the metastasis was established by ultrasound scanning.
Subsequently, the microdialysis system was connected and
perfused with Ringer’s solution at a flow rate of 1.5mlmin
 1 by a
microinfusion-pump (Precidor
s; Infors-AG, Basel, Switzerland).
After a 30min baseline sampling period, probe calibration for
capecitabine and FU was performed for a period of 30 min
according to a retrodialysis procedure (Stahle et al, 1991). After a
wash-out period of 30min, the study drug was administered in the
scheduled dose. Sampling was continued at 30-min intervals up to
300min. This interval corresponds to four plasma half-lives of the
metabolite DFCR (half-life: 1.22h) as the most slowly eliminating
compound (Mackean et al, 1998).
As a prerequisite for this study, several quality control
parameters were assessed using an in vitro microdialysis system.
The recovery was absolutely constant over 2h for capecitabine,
DFCR, DFUR, and FU. For these compounds, the recovery was
independent of the concentration up to 25mgml
 1. The lowest
recovery was observed for the most lipophilic compound
capecitabine (51.8%) when compared with the most hydrophilic
substance FU (72.9%) with intermediate recoveries for the
nucleosides DFCR and DFUR (60.7 and 61.8%, respectively). Since
the in vivo recovery of DFCR and DFUR could not be evaluated
and considering that both metabolites behave similar to FU (no
plasma protein binding as shown below and in vitro recoveries
similar to FU), DFCR and DFUR were calculated using the in vivo
recovery of FU.
In parallel, a plastic cannula was inserted into an antecubital
vein to monitor blood concentrations of the study drug at 30-min
intervals. A total of 10 capecitabine-naive patients were studied
after the first morning dose of day 1. Three of them were
monitored once again between days 12 and 14 of cycle 1.
Analysis of samples
Sample collection and analysis of microdialysates and blood
samples by capillary electrophoresis were performed according to
a validated method with minor modifications (Mader et al, 1998).
After thawing, 100ml plasma were centrifuged through Centrisart-
C4 filter units with a nominal molecular weight cutoff¼10000
(Sartorius, Germany) for 30min at 371C to separate free drug from
protein-bound drug. After ultrafiltration, the analytical results
obtained from blood samples were directly compared with those
obtained from microdialysates, which contained only free drug.
Capecitabine, DFCR, DFUR (supplied by Roche, Basel, Switzer-
land), and FU (Sigma, St Louis, MO, USA) were evaluated in
200mM tetraborate buffer (pH¼9.5) monitoring the absorbance at
three different wavelengths (capecitabine: 297nm, DFCR: 282nm,
DFUR and FU: 268nm). Typical migration times were 10.4min for
DFCR, 12.9min for capecitabine, 17.8min for FU, and 19.3min for
DFUR. The detection limit was 0.1mgml
 1 for all evaluated
compounds. The intra-assay coefficient of variation for this
method ranged from 3.4 to 6.9% with an interassay coefficient of
variation ranging from 6.7 to 10.4%.
The plasma protein binding of DFCR, DFUR, and FU was o4%
up to 100mg substance (ml plasma)
 1. In contrast, the plasma
protein binding of capecitabine was determined to be 60% by in
vitro binding experiments (data not shown).
Data analysis
To obtain absolute interstitial concentrations from dialysate
concentrations, microdialysis probes were calibrated for in vivo
recovery rates according to the retrodialysis method (Mu ¨ller et al,
1995, 1997). The principle of this method relies on the assumption
that the diffusion process is quantitatively equal in both directions
across the semipermeable membrane. Therefore, the study drug is
added to the perfusate and the disappearance rate through the
membrane is taken as the in vivo recovery. The in vivo recovery
value is calculated as:




In the present study, the recovery of capecitabine was similar to
that of FU in both tissues (rangecapecitabine in tumour: 11–58%,
rangeFU in tumour: 13–75%, rangecapecitabine in subcutaneous
connective tissue: 13–65%, rangeFU in subcutaneous connective
tissue: 12–69%).
Absolute interstitial fluid concentrations of free drug were





To avoid interferences with the subsequent pharmacokinetic
investigation, a very low concentration of capecitabine and FU was
used for the retrodialysis in vivo (2mgml
 1). The very small
amount of drug transferred into tissue during the retrodialysis
(90ng of each substance using a flow rate of 1.5mlmin
 1 over
30min) resulted in blank electropherograms after a wash-out
period of 30min.
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sThe following pharmacokinetic parameters were determined:
AUC calculated using the trapezoidal rule, maximum concentra-
tion (cmax), time to maximum concentration (tmax), and elimina-
tion half-life (t1/2). For statistical calculations, pharmacokinetic
parameters derived from different compartments were compared
using the paired Wilcoxon test.
RESULTS
After peroral administration to capecitabine-naive patients, the
pharmacokinetics of capecitabine varied considerably from patient
to patient when considering the systemic circulation (capecitabine
in plasma, range of cmax: 0.64–15.4mgml
 1, range of tmax: 1.0–
3.0h). Common features of the plasma pharmacokinetics included
the dominance of metabolism in the form of the FU precursors
DFCR and DFUR (Table 1). In contrast to FU, plasma concentra-
tions observed after i.v. infusion, this regimen was characterised
by low FU levels rarely exceeding 0.5mgml
 1 plasma (Figure 1A).
Considering distribution processes, capecitabine and its meta-
bolites DFCR and DFUR easily penetrated malignant and healthy
tissues (Figure 1B and C). Equilibration between plasma and tissue
interstitium occurred within 45min as determined from the time
interval between the peak concentrations in plasma and tissue
(Table 1).
In the malignant lesion, the exposure to capecitabine was
significantly higher when compared with plasma (AUC in tumour
vs plasma: P¼0.01), whereas the AUC of all other metabolites did
not differ significantly between malignoma and plasma. Compar-
ing the interstitium of subcutaneous connective tissue with
plasma, only the AUC of DFUR was significantly lower in healthy
tissue (P¼0.014). There was, however, a trend for higher exposure
to capecitabine in subcutaneous tissue in a subgroup of four
patients (ratio AUCconnective tissue/AUCplasma42).
FU observed in the systemic circulation equilibrated rapidly into
interstitial fluid without preference for malignant or healthy tissue.
Considering tissue exposure of all evaluated compounds (in terms
of AUC), no statistically significant differences were observed in
the interstitial space of malignant lesions and subcutaneous
connective tissue.
Since there is modest enzymatic activation of capecitabine
already in the stomach followed by rapid distribution from blood
to tissue, we questioned the tissue-specific transfer among these
compounds as expressed in the ratio AUC tissue/AUC plasma
(Table 2). Capecitabine showed significantly higher differential
transfer to the metastatic lesion when compared with the
metabolites DFCR (ratio AUC tumour/AUC plasma of capecitabine
vs DFCR: P¼0.004) and DFUR (P¼0.002). A similar observation
was made for subcutaneous connective tissue (ratio AUC
connective tissue/AUC plasma of capecitabine vs DFCR:
P¼0.002; ratio AUC connective tissue/AUC plasma of capecita-
bine vs DFUR: P¼0.002). Considering the ratio AUC tumour/AUC
connective tissue for all evaluated compounds, there was no
statistically significant difference between both tissues. When
considering the maximum concentration, however, the ratio cmax
tumour/cmax connective tissue of FU was significantly lower than
that of all other evaluated compounds (ratio cmax tumour/cmax
connective tissue of capecitabine vs FU: P¼0.05; DFCR vs FU:
P¼0.03; DFUR vs FU: P¼0.05). Besides statistical calculations, FU
peak concentrations in connective tissue exceeded twice that of
malignant tissue in six of 10 capecitabine-naive patients. Given the
constantly low concentrations of FU in plasma and in interstitial
Table 1 Pharmacokinetic parameters
a of capecitabine and its metabolites in plasma, malignant tissue, and healthy
connective tissue
Compartment Parameter Capecitabine DFCR DFUR FU
Plasma cmax (mgml
 1) 2.34 6.53 3.65 0.25
(0.64–15.4) (1.79–8.7) (1.67–7.22) (0.09–0.80)
tmax (h) 1.75 1.75 2.0 2.5
(1.0–3.0) (1.0–3.0) (1.0–3.0) (1.0–3.5)
T1/2 (h) 0.50 0.86 0.80 N.A.
(0.21–0.92) (0.6–2.33) (0.44–2.44)
AUC0 5h (mgml
 1h) 2.36 11.3 6.42 0.29
(1.13–17.3) (4.74–16.5) (4.26–10.0) (0.13–1.86)
Tumour cmax (mgml
 1) 2.66 4.22 2.13 0.26
(0.91–15.7) (1.54–4.29) (0.85–4.29) (0–0.74)
tmax (h) 2.5 2.5 2.5 3.0
(1.5–3.5) (1.5–3.5) (1.5–4.0) (1.0–4.5)
t1/2 (h) 0.50 0.87 1.08 N.A.
(0.27–1.24) (0.43–1.59) (0.48–2.17)
AUC0 5h (mgml
1h) 3.52 7.89 3.35 0.25
(0.92–33.3) (2.15–25.2) (1.43–13.4) (0–2.28)
s.c. Tissue cmax (mgml
 1) 2.70 4.37 1.51 0.33
(0.58–28.2) (1.11–10.1) (0.70–5.87) (0.08–1.40)
tmax (h) 2.25 2.5 2.75 2.0
(1.0–3.5) (1.5–3.5) (1.5–3.5) (0.5–3.5)
t1/2 (h) 0.59 0.76 0.82 N.A.
(0.17–1.5) (0.57–3.57) (0.64–2.80)
AUC0 5h (mgml
 1h) 3.16 8.40 2.75 0.36
(0.78–43.5) (2.31–22.1) (1.51–11.6) (0.13–2.21)
Patients received 1250mg capecitabinem
 2 orally with tap water before collecting plasma samples and interstitial tissue fluid up to
5h after administration.
aValues are reported as median and range in parentheses (n=10). DFCR=50-deoxy-5-fluorocytidine; DFUR=50-deoxy-5-
fluorouridine; FU=5-fluorouracil; cmax=maximum concentration; tmax=time to maximum concentration; t1/2=elimination half-life;
AUC0 5h=area under the concentration-time curve from 0 to 5h; NA=not applicable.
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stissue fluid, no correlation between pharmacodynamics and tissue
FU kinetics could be established. The highest haematologic toxicity
was observed in one patient with anaemia WHO grade 2 and four
patients suffering from anaemia WHO grade 2.
To consider repeated administration of capecitabine, drug
monitoring was repeated at the end of the first therapeutic cycle
in three patients (days 12–14). In one of these patients, absorption
and distribution were subject to remarkable variations between
different drug applications. Nevertheless, this patient illustrates a
close relation between plasma kinetics and interstitial tissue
kinetics observed throughout this study. When capecitabine was
administered on day 1, the metabolites DFCR and DFUR did not
exceed plasma concentrations of 4mgml
 1 in one patient because
of slow absorption kinetics without pronounced absorption
maxima. Although FU was detected in plasma and in the
connective tissue of this patient, FU was not observed in the
tumour interstitium. When given at the end of the first cycle,
absorption started later in comparison to day 1, but the plasma
concentrations of the metabolites DFCR and DFUR were about
10mgml
 1 with clearly defined absorption maxima. In addition,
the distribution into subcutaneous connective tissue was high on
day 1, but was low at the end of the first cycle (Figure 2A–C).
During this administration, the concentrations and the AUC of FU
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Figure 1 Concentration–time profiles of capecitabine and its metabolites in patients with advanced breast cancer. Patients received 1250mg
capecitabinem
 2 orally with tap water before collecting plasma samples and interstitial tissue fluid up to 5h after administration. Concentration–time profile
in plasma (A), concentration–time profile in the interstitium of malignant tissue (B), concentration–time profile in the interstitium of subcutaneous
connective tissue (C). Concentrations are depicted as means of the single courses 7 s.e. (n¼10). 50-DFCR¼50-deoxy-5-fluorocytidine; 50-DFUR¼50-
deoxy-5-fluorouridine; 5-FU¼5-fluorouracil.
Table 2 Transcapillary transfer
a of capecitabine and its metabolites to malignant and healthy
tissues
Ratio of AUC0 5h Capecitabine DFCR DFUR FU
Tumour/plasma 1.76 0.67 0.53 0.66
(0.54–7.07) (0.45–2.97) (0.28–2.56) (0–5.56)
s.c. Tissue/plasma 1.31 0.67 0.44 1.53
(0.46–16.7) (0.41–2.60) (0.25–1.36) (0.32–3.38)
Tumour/s.c. tissue 1.11 1.12 1.20 0.66
(0.36–1.99) (0.55–1.93) (0.60–3.07) (0–17.5)
aRatios are reported as median and range in parentheses as calculated from each single patient (n=10). See
Table 1.
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Figure 2 Concentration–time profiles of capecitabine and its metabolites in one patient on day 12. Patients received 1250mg capecitabinem
 2 orally
with tap water before collecting plasma samples and interstitial tissue fluid up to 5h after administration. Concentration–time profile in plasma (A),
concentration–time profile in the interstitium of malignant tissue (B), concentration–time profile in the interstitium of subcutaneous connective tissue (C).
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spatients, the differences from course to course were in the
range expected after peroral administration as estimated by
the ratio of AUC and cmax (differences between the courses in
general o35%).
DISCUSSION
The peroral formulation of capecitabine has spurred new
expectations exploiting the efficiency of the well-known antime-
tabolite FU in cancer chemotherapy. For the time being, the
description of the systemic pharmacokinetics of capecitabine is
only matched sporadically by pharmacokinetic data derived from
human tumours in vivo. Besides tumour xenografts, there is
evidence of a selective enrichment of FU in colorectal tumours.
Considering the concentration of FU in tissue biopsies, the median
ratio tumour/healthy tissue was 2.9 with a median tumour/plasma
ratio of 16.6. In secondary lesions, no selectivity towards liver
metastases vs healthy liver tissue was observed (Schu ¨ller et al,
2000). Limitations of biopsies, however, are the lack of discrimina-
tion among different organ compartments, that is, the intracellular
space and the interstitial fluid, and the sporadic sampling
frequency. To gain further insight into the tissue pharmacokinetics
of capecitabine using continuous monitoring, the microdialysis
technique was employed in the present investigation.
After absorption, the distribution of capecitabine and its
metabolites occurred within 45min into tissue with little
discrimination for malignant and subcutaneous connective tissues.
The data shown in Figure 2 emphasise the absorption of
capecitabine as a decisive step for the interstitial tissue kinetics
of capecitabine and its metabolites. As a consequence, blood peak
levels of the monitored compounds were similar to those in tissue
interstitium. With exception of the parent drug capecitabine, the
complete equilibration between plasma and tissue interstitium
precluded significant accumulation of the metabolites. Thus, the
carboxylic side chain of capecitabine is believed to be responsible
for the enhanced tissue affinity of the parent drug, which is then
lost after conversion to its metabolites.
The efficacy of capecitabine relies on the cytotoxic mechanisms
of FU. Once entered the cell, the balance between anabolic
conversion to the cytotoxic species and catabolic degradation
determines the pharmacodynamic activity. We have previously
shown that the extravascular transfer of FU may be a critical
parameter in determining the clinical response (Mu ¨ller et al, 1997).
After i.v. administration of FU, its transfer into primary breast
cancer lesions was impaired in nonresponders. In the present
investigation, the rapid and quantitative equilibration of capeci-
tabine and its metabolites between plasma and tissue interstitium
left little space for resistance to capecitabine caused by impaired
tissue transfer of the parent drug or its metabolites.
Schu ¨ller et al (2000) have shown that at least in the colon and in
the liver, the intracellular catabolism of FU via dihydropyrimidine
dehydrogenase is similar in healthy and malignant tissues. As a
consequence, it is reasonable to assume that the expected toxicity
in healthy tissue will largely depend on the last activation step,
which is the intracellular conversion of DFUR to FU via thymidine
phosphorylase. In this context, the differential affinity of FU to
subcutaneous connective tissue when compared with malignant
tissue may offer a starting point to unravel the mechanism
underlying the hand–foot syndrome, which may restrict ther-
apeutic interventions with capecitabine. Although there was no
statistically significant difference between FU pharmacokinetics in
connective and malignant tissues, FU peak concentrations
indicated an increased transfer into connective tissue in six of 10
patients. None of these patients, however, suffered from a hand–
foot syndrome suggesting the additional effect of factors beyond
FU as mechanism for this side effect. Although the activity of this
enzyme was not the aim of the present investigation, one may
hypothesise that the higher FU levels in the connective tissue of
more than half of the patients did not result in toxic side effects
because of lacking activation of DFUR to FU via thymidine
phosphorylase. This is compatible with several previous observa-
tions about the pivotal role of this enzyme in the antiproliferative
effect of FU (Schwartz et al, 1995; Ciccolini et al, 2001) and DFUR
(Evrard et al, 1999a). Moreover, our data suggest that once
converted to FU intracellularly, this agent is hardly redistributed to
the systemic circulation thus contributing to the mild systemic side
effects of large doses of capecitabine.
Surprisingly, there was little selectivity for the evaluated
compounds when comparing the interstitium of malignant and
healthy tissues. This may be partly because of the specific nature of
skin metastases in terms of vascularisation and/or differential
thymidine phosphorylase activity, which varies considerably
among various tissues (Ackland and Peters, 1999). Given that the
microdialysis technique allows for the monitoring of the extra-
cellular space only, intracellular tissue selective activation can only
be monitored after efflux of the metabolite from the cell. Therefore,
intracellularly generated nucleosides and nucleotides such as
fluorodeoxyuridine monophosphate, fluorodeoxyuridine tripho-
sphate, and fluorouridine triphosphate cannot be directly assessed
using this approach, because they are trapped within the cell after
phosphorylation.
In the tumour, the activity of thymidine phosphorylase may be
critical, because this enzyme plays a double role in the activation of
capecitabine. Depending on the cellular concentration, thymidine
phosphorylase is able to convert DFUR to FU intracellularly, but
also to further activate FU to fluorodeoxyuridine. Only then, the
cytotoxic potency of FU is fully exploited. Unfortunately, the
regulation of this enzyme is not completely understood. In vitro,
the expression of thymidine phosphorylase was subject to little
variation after exposure of naive colon tumour cells to FU (Mader
et al, 1997). Its importance in the conversion of FU, however, has
been definitely confirmed (Evrard et al, 1999a,b). Thus, in
addition to impaired absorption of capecitabine, the activity of
thymidine phosphorylase is very likely to be a critical factor in the
therapy with capecitabine.
For an agent administered daily, one of the most important
clinical questions considers possible alterations of pharmacologic
parameters with time. As shown for the small number of three
patients, the repeated administration did not alter the tissue
transfer or the metabolism of the drug significantly. Since at least
two of the enzymes involved in the activation of capecitabine, that
is, carboxylesterase and cytidine deaminase, may be monitored via
the rate of the formation of the metabolites DFCR and DFUR in
plasma, one may assume a stable metabolic situation within one
therapeutic cycle (28 administrations) with a daily dose of 2500mg
capecitabinem
 2. Although the limited number of observations
precludes definite conclusions, these data suggest the absence of
pharmacokinetic mechanisms related to capecitabine resistance.
Since patients did previously receive anthracycline- or taxane-
based regimens, one possible mechanism of resistance should
consider upregulation of MDR1/P-glycoprotein. In this study, the
hydrophilic metabolites DFCR and DFUR were mainly observed in
tissue interstitium. Although upregulation of MDR1/P-glycopro-
tein may be observed for a median period of 4 months after
therapy with modulating agents such as anthracyclines or taxanes
(M Filipits, personal communication), there is no evidence in the
literature that the cellular uptake of FU and fluoropyrimidine
nucleosides is influenced by the expression of MDR1/P-glycopro-
tein.
Although one restriction of the microdialysis technique is the
inability to monitor intracellular processes, this technique allows
for the evaluation of drugs in a well-defined tissue compartment,
namely the extravascular interstitial tissue fluid. This is in contrast
to all other analytical techniques applied to fluoropyrimidine
pharmacokinetics such as tumour biopsies or NMR-studies, which
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sconcomitantly monitor signals in intra- and extracellular compart-
ments.
The results from this study show that capecitabine and its
metabolites DFCR and DFUR distribute extensively into the
interstitium of malignant and healthy tissues. This efficient
penetration into the interstitium of malignant tissue is the initial
necessary step before DFUR enters tumour cells, where it is
converted to FU by thymidine phosphorylase. The results obtained
in the present study are complementary to those obtained
previously by Schu ¨ller et al (2000), who reported a mean tumour/
plasma ratio of 21 for FU in patients with colorectal tumours. This
very high concentration of FU in malignant tissue compared to
plasma could only be achieved because, as a first step, the
precursors of FU distributed very efficiently into the interstitium of
malignant tissue, as demonstrated in the present study.
In conclusion, capecitabine and its metabolites DFCR and DFUR
easily penetrated malignant and healthy tissues with little
selectivity among both types of tissues. Concomitantly, the
concentrations of FU were low in blood and in the interstitium
of malignant and healthy tissues. Our data show that absorption
and metabolism determined the tissue pharmacokinetics of
capecitabine. There was no evidence of drug tolerance, which
may be attributed to impaired transcapillary transfer into tissue,
even after repeated administration of capecitabine as shown for
three patients.
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